| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 27 Jan 2025 | 18 Jan 2025 |
| Epigral Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2025 inter alia to consider and approve Un-Audited Financial Results for the Third Quarter and Nine Months ended on 31st December 2024 and to declare Interim Dividend on the equity shares of the Company for the Financial Year 2024-25. Outcome of Board Meeting held on Monday, 27th January, 2025 containing submission of Un-Audited Financial Results (Standalone & Consolidated) for the Third Quarter and Nine Months ended on 31st December, 2024 and Declaration of interim dividend of Rs. 2.50 (25%) per Equity Share of face value of Rs. 10/- each for the Financial Year 2024-25. (As Per BSE Announcement Dated on 27/01/2025) | ||
| Board Meeting | 9 Nov 2024 | 29 Oct 2024 |
| Quarterly Results Outcome of Board Meeting held on Saturday, 9th November, 2024 and submission of Un-Audited Financial Results (Standalone & Consolidated) for the Second Quarter and Half Year ended on 30th September, 2024. UFR - 30.09.2024 Expansion of production capacity of CPVC and Epichlorohydrin at Dahej, Gujarat. (As Per BSE Announcement Dated on 09.11.2024) | ||
| Board Meeting | 14 Aug 2024 | 9 Aug 2024 |
| Epigral Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve inter alia proposal for raising of funds through issuance of instruments or security including equity shares or any other eligible securities by way of one or more public and/or private offerings including on a preferential allotment basis and/or a qualified institutions placement subject to such regulatory statutory approvals as may be required including approval of the shareholders of the Company. Raising of funds through issuance of instruments or security including equity shares or any other eligible securities by way of one or more public and/or private offerings including on a preferential allotment basis and/or a qualified institutions placement for an amount not exceeding Rs.500 Crores (Rupees Five Hundred Crores Only). (As Per BSE Announcement Dated on 14.08.2024) | ||
| Board Meeting | 24 Jul 2024 | 16 Jul 2024 |
| Epigral Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2024 inter alia to consider and approve Un-audited Financial Results for Quarter ended 30th June 2024. Epigral Limited submits the unaudited financial results for the quarter ended on 30.06.2024. Outcome of Board Meeting held on Wednesday, 24th July, 2024 and submission of Un-Audited Financial Results (Standalone & Consolidated) for the First Quarter ended on 30th June, 2024 Epigral Limited (formerly known as Meghmani Finechem Limited) copy of Newspaper Publication pertaining to Un-audited Financial Results for quarter ended 30.06.2024. (As per BSE Announcement Dated on 24/07/2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
